David Kerr (oncologist)

From WikiProjectMed
Jump to navigation Jump to search

David James Kerr
CBE, MA MD DSc FRCP (Glas & Lon) FRCGP (Hon) FMedSci
Born1956
Glasgow, Scotland
NationalityBritish
EducationUniversity of Glasgow – MD (1987), BSc-Biochemistry (1977)
Years active1992-present
Known forResearch and Treatment of colorectal cancer; Gene Therapy
Medical career
ProfessionMedical Doctor, researcher
FieldOncology
InstitutionsOxford University
ResearchColorectal Cancer, Gene Therapy
Awards
  • Distinguished Harvard Global Health Catalyst Award (2017)
  • Honorary Fellowship of the Royal College of General Practitioners (2007)
  • European Society for Medical Oncology Award(2006)
  • Commander of the Order of the British Empire (2002)
  • NHS Nye Bevan Award for Innovation (2000)
  • European School of Oncology International Award for outstanding contribution to chemotherapy research (1987)

Professor David James Kerr CBE (born 1956, Glasgow)[1] is a British Cancer Researcher. His primary area of research is treatment and management of colorectal cancer.[2]

He served as Chief Research Advisor at Sidra Medical and Research Center in Doha, Qatar.[3][4] David James Kerr is Professor of Cancer Medicine and Former Fellow of Corpus Christi College, Oxford.[5] He was also President-Elect for European Society for Medical Oncology (2009).[6]

David James Kerr’s clinical research into adjuvant therapy of early-stage colorectal cancer has contributed to saving thousands of lives over the past two decades.[7]

Early life and education

Kerr was born in 1956 in Glasgow. He attended Dunard Street Primary School, Maryhill, and Eastwood High Secondary School. Knowing from a relatively early age that he wanted to become a doctor having read A. J. Cronin's The Citadel as a child, he went on to study biochemistry and medicine at Glasgow University, and subsequently became an ontological clinical scientist[8] following specialist and fellowship training within the Department of Medical Oncology at the University of Glasgow under Professor S. Kaye (1984–1992).[1]

Career

Beginning in March 1992, Kerr served as Professor of Clinical Oncology at the University of Birmingham and Director of the Clinical Trials Unit where he and Professor Alan Rickinson built the Institute of Cancer Studies.[9]

In 1994, he was appointed Clinical Director of the Regional Cancer Task Force for the West Midlands.[1] There, he developed a "hub and spoke" Network model for cancer services in the region. The key elements of the plan are:

  • Site specialization by cancer surgeons and oncologists
  • Multidisciplinary working
  • Development of regional treatment guidelines (often precursor of national guidelines)
  • Use of IT as a social glue to bind the network together.

He undertook the first national audit of cancer waiting times for Sir Kenneth Calman, who was then Chief Medical Officer which was one of the drivers which led to the Government creating a National Cancer Plan.[1][10]

In 2001, he was appointed Rhodes Professor of Clinical pharmacology and Cancer Therapeutics[11] and Head of the Department of Clinical Pharmacology at the University of Oxford. At the same time, he was also asked by the Secretary of State for Health Alan Milburn to undertake a review of NHS research strategy into cancer.[12] The resultant blueprint for the provision of infrastructure to support clinical cancer research in the UK led to the establishment of the NHS Cancer Research Network (NCRN)[13] and the National Translational Cancer Research Network (NTRAC). Kerr was subsequently appointed the Director of NTRAC.[14]

He subsequently worked with colleagues to build an Institute of Cancer Medicine and Cancer Treatment Center in Oxford.[citation needed]

In 2004, Kerr was invited by Scotland’s First Minister to chair the work of a National Framework Advisory Group to consider the future shape of the NHS in Scotland. This Group produced three volumes of work, "Building a Health Service Fit for the Future" (Vol I and II) and a web-based data link showing the Reports from the individual action teams.[15] This has been adopted as the blueprint for Scotland’s NHS over the next 20 years.

In 2009, David Kerr temporarily left Oxford University to serve as the Chief Research Advisor at the Sidra Medical and Research Center. He also became a Member of the Supreme Council of Health in April 2009. Although he has since returned to the UK and is no longer affiliated with Sidra, Kerr has made significant contributions to cancer care and research in Europe. He played a leading role in co-chairing the Anglo-French Scientific committee for the centenary of the Entente-Cordiale in 2004, focusing on cancer research as the joint theme of the Queen and President Chirac. Additionally, Kerr successfully established the first network of top cancer centers in India, transforming it into a globally recognized trials network and providing training for numerous young Indian oncologists.[citation needed]

He has brought worldwide attention to the looming epidemic of cancer which is a risk of claiming the lives of more than a million Africans every year.[16] He organized the first ever African Cancer Reform convention in London (2007).[17] This was attended by 27 African Health ministries, led to the London Declaration calling for immediate action to develop cancer control plans for these nations.[18] Subsequently Kerr was asked by African ministers to lead a new organization, AfrOx to aid national cancer planning in Africa. AfrOx has already received international support (WHO, IAEA) and is seen as a beacon to establish cancer care in Africa. He has completed a National Cancer Plan for Ghana, has been invited by the governments of Rwanda, Nigeria and Sierra Leone to lead their cancer plan activities, has initiated a mass vaccination program for cervical cancer, the commonest cancer affecting African women, and is coordinating the International Oncology Association's engagement in this field.[citation needed]

Kerr spoke at a New Frontiers in Science Diplomacy event[19] and blogged on the Guardian[20] about it.

Published works

Kerr has published over 350 papers in peer reviewed journals. His primary areas of research are colorectal cancer and gene therapy. He has been awarded several patents which have led to spin out biotech companies – Cobra Therapeutics,[21] Oxford Cancer Biomarkers,[22] and Celleron Therapeutics.[23]

He sits on a number of general editorial boards including Nature Reviews Clinical Oncology journal.

Awards and honours

References

  1. ^ a b c d "David Kerr new Editor-in-Chief of Annals of Oncology | Annals of Oncology | Oxford Academic" (PDF). Annonc.oxfordjournals.org. 1 September 1999. Retrieved 25 December 2018.[dead link]
  2. ^ Sidra Medicine. "Sidra Medicine | Hospital in Qatar" (PDF). Sidra.org. Retrieved 25 December 2018.[permanent dead link]
  3. ^ "New frontiers in science diplomacy" (PDF). The Royal Society Science Policy Centre. January 2010. p. 32. Retrieved 24 May 2023.
  4. ^ Kermani, Faraz (4 March 2010). "How to run clinical trials in the Middle East - Qatar". Scrip World Pharmaceutical News.
  5. ^ Sidra Medicine. "Sidra Medicine | Hospital in Qatar". Sidra.org. Retrieved 25 December 2018.[permanent dead link]
  6. ^ "European Society for Medical Oncology Committees | Annals of Oncology | Oxford Academic" (PDF). Annonc.oxfordjournals.org. 1 September 2008. Retrieved 25 December 2018.[dead link]
  7. ^ Lancet, 370(9604):2020-9. 2007; The Lancet, 355, 1588–96 (2000)
  8. ^ "Cancer hit squad". Archived from the original on 5 December 2008. Retrieved 3 September 2009.
  9. ^ The Committee Office, House of Commons. "House of Commons - Science and Technology - Appendices to the Minutes of Evidence". Publications.parliament.uk. Retrieved 25 December 2018.
  10. ^ British Medical Journal 320, 838–839.
  11. ^ "Oxford University Gazette, 11 January 2001: Notices". Archived from the original on 2 September 2007. Retrieved 3 September 2009.
  12. ^ The Committee Office, House of Commons. "House of Commons - Science and Technology - Minutes of Evidence". Publications.parliament.uk. Retrieved 25 December 2018.
  13. ^ "Archived copy" (PDF). Archived from the original (PDF) on 16 October 2009. Retrieved 3 September 2009.{{cite web}}: CS1 maint: archived copy as title (link)
  14. ^ The Committee Office, House of Commons. "House of Commons - Science and Technology - Appendices to the Minutes of Evidence". Publications.parliament.uk. Retrieved 25 December 2018.
  15. ^ framework
  16. ^ "Africa's looming cancer epidemic". BBC News. 12 June 2008. Retrieved 1 May 2010.
  17. ^ "Untitled Document". Archived from the original on 18 April 2009. Retrieved 3 September 2009.
  18. ^ "Archived copy" (PDF). Archived from the original (PDF) on 1 September 2009. Retrieved 3 September 2009.{{cite web}}: CS1 maint: archived copy as title (link)
  19. ^ "Sorry". Royal Society. Retrieved 25 December 2018.
  20. ^ Kerr, David (22 June 2009). "Science can bridge national divides". The Guardian. London. Retrieved 1 May 2010.
  21. ^ "Celleron Therapeutics - Management". Archived from the original on 8 July 2011. Retrieved 3 September 2009.
  22. ^ "Oxford Cancer Biomarkers – Pioneering precision medicine". Oxfordbio.com. Retrieved 25 December 2018.
  23. ^ "Celleron Therapeutics". Celleron Therapeutics. Retrieved 25 December 2018.
  24. ^ a b c http://www.worldgicancer.com/WCGI/WGIC2009/About%20ESMO.pdf[permanent dead link]
  25. ^ a b "Professor David Kerr – Department of Clinical Pharmacology". University of Oxford. 19 June 2008. Archived from the original on 23 April 2010. Retrieved 3 September 2009.
  26. ^ "'NHS Oscars' Awarded To NHS Modernisers". 5 July 2005.
  27. ^ "New Year's Honours List — United Kingdom". The London Gazette. 31 December 2001. p. 8. ISSN 0374-3721. Retrieved 24 May 2023.
  28. ^ "Awards and Fellowships 2007" (PDF). Royal College of General Practitioners.[permanent dead link]

External links

Retrieved from "https://mdwiki.org/wiki/David_Kerr_(oncologist)"